# Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus

> **NCT02535689** · PHASE1 · COMPLETED · sponsor: **National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)** · enrollment: 34 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** Tofacitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02535689
- **Lead sponsor:** National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-28
- **Primary completion:** 2018-04-26
- **Final completion:** 2018-04-26
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2018-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02535689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02535689, "Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02535689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*